RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx today announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial has been published online in connection with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 29 – June 2, 2026.